Plain Language Summary

Full results and Plain Language Summary for CheckMate 77T trial – NEJM

NEJM shared on X/Twitter:

“In the CheckMate 77T trial, researchers assessed whether adding adjuvant nivolumab to neoadjuvant nivolumab plus chemotherapy would improve outcomes in patients with resectable non–small-cell lung cancer (NSCLC). Full results and Plain Language Summary.”

Perioperative Nivolumab in Resectable Lung Cancer A PLAIN LANGUAGE SUMMARY Top Figure: Illustration of treatment options during the Neoadjuvant and Adjuvant Periods. Bottom Figure: Graph of the Percentage of Patients with Event-free Survival

Source: NEJM/X

adjuvant nivolumab cancer CheckMate 77T trial NEJM neoadjuvant nivolumab OncoDaily Oncology resectable NSCLC